Aquestive Therapeutics Inc

Discover how AQST’s delayed CNS drug approval and legal scrutiny shape its valuation and investor confidence, and what the upcoming Oppenheimer conference could mean for its future.

AQST shares surge 43% after FDA’s CRL for Anaphylm, showcasing investor optimism amid a planned resubmission and potential rapid review.

Explore how Aquestive Therapeutics’ late‑stage CNS drug pipeline and recent financial metrics paint a picture of risk and potential recovery for investors.

Discover how Aquestive Therapeutics’ new leadership, analyst upgrades, and upcoming FDA‑approved Anaphylm™ are shaping its stock and pipeline prospects.

Aquestive Therapeutics, a pharmaceutical company, is navigating market volatility amidst strategic developments, with its stock price experiencing significant fluctuations due to challenges in maintaining its market position and revenue streams.

Aquestive Therapeutics reported a modest 1.49% revenue increase in Q1 2025, but faces ongoing challenges in achieving profitability with a projected loss per share of -$0.663 for the current fiscal year.

Aquestive Therapeutics Inc. is a pharmaceutical company focused on central nervous system diseases, navigating challenges and opportunities in the industry with a commitment to innovation and patient care.